Given that identifying 1p/19q status is needed to distinguish between IDH mutant astrocytoma and oligodendroglioma, and the high cost of genetic testing needed to identify it, the HIP1R/vimentin/ATRX approach could serve as an easy and reliable surrogate in clinical practice. The gene discussed is ATRX; the disease is astrocytoma (excluding glioblastoma).